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Unravelling the specificity of laminaribiose phosphorylase from 
Paenibacillus sp. YM-1 towards donor substrates 
glucose/mannose 1-phosphate using X-ray crystallography and 
STD NMR spectroscopy 
Sakonwan Kuhaudomlarp,[a] Samuel Walpole,[b] Clare E.M. Stevenson,[a] Sergey A. Nepogodiev,[a] 
David M. Lawson,[a] Jesus Angulo,[b] Robert A. Field *[a] 
 
Abstract: Glycoside phosphorylases (GPs) carry out a reversible 
phosphorolysis of carbohydrates into oligosaccharide acceptors and 
the corresponding sugar 1-phosphates. The reversibility of the 
reaction enables the use of GPs as biocatalysts for carbohydrate 
synthesis. Glycosyl hydrolase family 94 (GH94), which only comprises 
GPs, is one of the most studied GP families that have been used as 
biocatalysts for carbohydrate synthesis, in academic research and in 
industrial production. Understanding the mechanism of GH94 
enzymes is a crucial step towards enzyme engineering to improve and 
expand the applications of these enzymes in synthesis. In this work 
with a GH94 laminaribiose phosphorylase from Paenibacillus sp. YM1 
(PsLBP), we have demonstrated an enzymatic synthesis of 
disaccharide 1 (b-D-mannopyranosyl-(1®3)-D-glucopyranose) using 
natural acceptor glucose and non-cognate donor substrate a-
mannose 1-phosphate (Man1P). To investigate how the enzyme 
recognizes different sugar 1-phosphates, we solved the X-ray crystal 
structures of PsLBP stin complex with Glc1P and Man1P, providing 
the first molecular detail of the recognition of a non-cognate donor 
substrate by GPs, which revealed the importance of hydrogen 
bonding between the active site residues and hydroxyl groups at C2, 
C4 and C6 of sugar 1-phosphates. Furthermore, we used STD NMR 
to support the crystallographic studies on the sugar 1-phosphates, as 
well as to provide further insights into the PsLBP recognition of the 
acceptors and the disaccharide products.  
Introduction 
Glycoside phosphorylases (GPs) are a group of 
carbohydrate-active enzymes that catalyse the reversible 
cleavage of glycosidic linkages in di- or oligo-saccharides by 
transferring non-reducing end glycosyl residue to inorganic 
phosphate.[1–4] The reverse reacton (synthetic reaction) of GPs is 
of practical importance because it can be used as an alternative 
method of enzymatic glycosylation utilizing sugar 1-phosphates 
as donor substrates. GPs have been classified based on their 
sequence identity into glycosyl hydrolase (GH) and glycosyl 
transferase (GT) families, or categorised into retaining and 
inverting phosphorylases, depending on the anomeric 
configuration in O-glycoside with respect to the sugar 1-
phosphate substrates. Substrates for GP-catalyzed 
glycosylations are more readily available in comparison to that for 
GT-catalyzed reactioins, making GPs attractive biocatalysts for   
carbohydrate syntheses. The use of GP biocatalysts have been 
demonstrated in academic research such as in the synthesis of 
homogeneous crytalline cellulose;[5] self-assembled structures of 
alkylated cellulose;[6] cellulose nanoribbon with primary amino 
groups;[7] and formation of  oligo(ethylene glycol)-bearing 
cellulose hydrogels;[8]  and more widely at industrial scale, such 
as for the synthesis of 2-O-(a-D-glucopyranosyl)-sn-glycerol,  a 
cosmetic ingredient, by sucrose phosphorylase;[9] kilogram scale 
synthesis of lacto-N-biose, a prebiotic made with lacto-N-biose 
phosphorylase;[10] and the synthesis of disaccharide sweetener 
kojibiose, produced with a sucrose phosphorylase variant from 
Bifidobacterium adolescentis.[11]  
 
One of the most studied GP families is found in GH94 which 
includes GPs acting on β-1,2 (sophorose),[12] β-1,3 
(laminaribiose) [13] and β-1,4-linked glycans (cellobiose,[14,15] 
cellodextrin,[16] chitobiose [17] and cellobionic acid [18]). Several 
characterised GH94 GPs show broad specificity towards non-
physiological acceptor substrates, including cellodextrin 
phosphorylase (CDP) from Clostridium sterococarium has been 
used to produce cellobiose-containing antioxidants.[19,20] 
Cellobiose phosphorylase (CBP) is capable of using xylose as an 
acceptor, to produce glucopyranosyl-xylose,[21,22] and simple 
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alcohols, producing alkyl b-glucosides.[23] While the relaxed 
acceptor specificity has been demonstrated, the specificity of GPs 
for sugar 1-phosphate is relatively narrow. The majority of GH94 
GPs use Glc1P as a donor substrate, with the exception of 
chitobiose phosphorylase (ChBP), which uses α-D-GlcNAc 1-
phosphate (GlcNAc1P) as its‘ natural donor,[17,24] although it can 
also use Glc1P with 20 times reduction in efficiency.[17] Relaxed 
donor specificity has also been demonstrated for CDP from 
Clostridium stercorarium, which can use either Glc1P or α-D-
galactose 1-phosphate (Gal1P) as its glycosyl donor for glycolipid 
synthesis, albeit with 10 times less efficiency on Gal1P.[25] Both 
CBP and CDP from Clostridium thermocellum are capable of 
using a-D-glucosyl fluoride as a donor for the synthesis of 
cellobiose and cellodextrin.[26] ChBP, which normally uses 
GlcNAc1P as its cognate donor.   
 
Numerous X-ray crystal structures are available for GH94 
enzymes, either in the presence of phosphate or sulphate (PDB 
code 2CQS, 3QDE, 3RSY, 2CQT),[27,28] the acceptors (PDB code 
3S4B, 1V7X, 5H40, 4ZLG and 5NZ8),[29–32] iminosugar inhibitors 
(PDB code 3QFY, 3QFZ, and 3QG0, 5H41),[31,33] or disaccharide 
products (PDB code 3S4A, 4ZLF).[32] These structures provide 
valuable resources that can be used to guide the engineering of 
GPs for non-cognate substrates. Structure-guided site-directed 
mutagenesis based has been performed extensively on 
cellobiose phosphorylase from Cellvibrio gilvus (CgCBP), 
including its‘ conversion to a lactose phosphorylase.[34] In addition, 
a single mutation (E649C) in CgCBP created an enzyme variant 
that is capable of using methyl b-glucoside, ethyl b-glucoside and 
phenyl b-glucoside as acceptors.[35,36] Another CgCBP variant 
was created by mutation of five amino acids within and around the 
entrance to the enzyme active, which broaden acceptor range to 
incude both b- and a-glucosides.[35]  In contrast to the situation of 
acceptor substrate studies, the number of reported GP structures 
in complex with the sugar donors are relatively limited, with only 
a β-1,2-glucan phosphorylase from Lachnocolostridium 
phytofermentans (LpSOGP) in complex with Glc1P being 
reported (PDB code 5H42),[31] which limits our understanding of 
the recognition of the sugar 1-phosphate donors by the GH94 
family. 
 
Whilst crystallographic studies provide valuable ‘snapshots’ of 
enzyme active sites, they do no capture the dynamics of the 
enzyme-ligand interaction in solution. Therefore, other techniques 
to study protein-ligand interactions in solution are needed to 
complement the crystallographic data. Saturation transfer 
difference nuclear magnetic resonance spectroscopy (STD NMR) 
was developed to study the protein-ligand binding interaction in 
solution, based on the transfer of magnetization from the protein 
protons to the protons of the ligand whilst the ligand is bound.[37] 
Those ligand protons in close contact with the protein exhibit the 
strongest STD NMR intensities, thus allowing the mapping of the 
ligand binding epitope.[38] STD NMR can be used to facilitate the 
study of protein-glycan interactions, which is often difficult to study 
in solution due to the weak affinity as well as the flexibility and 
complexity of the carbohydrate ligands. STD NMR has been used 
to elucidate the specificity of protein-glycan interactions on 
different sialoglycan structures,[39] and to reveal the importance of 
glycan polarity, which determines the interaction and subsequent 
biological activation of its receptor.[40] This technique has also 
been used to study enzyme-carbohydrate interactions to 
elucidate recognition features that can be used for inhibitor design, 
such as the study of ligand recognition by enzymes that are 
involved in mycobacterial cell wall biosynthesis, including UDP-
galactopyranose mutase [41,42] and 
galactofuranosyltransferases.[43] The same technique has been 
used to elucidate the binding of human blood group 
glycosyltransferases to their substrates, a process that is crucial 
to the biosynthesis of human blood antigen.[44,45]  
 
Following on from our efforts to understand GP structure-function 
relationships and their application in carbohydrate syntheses 
[30,46,47], herein we investigated the GH94 laminaribiose 
phosphorylase from Paenibacillus sp. YM-1 (PsLBP), which has 
previously been reported for its specificity towards laminaribiose 
(b-D-glucopyranosyl-(1®3)-D-glucopyranose) (Scheme 1A).[13]  
We have evaluated the activity of PsLBP on a non-cognate donor, 
α-D-mannose 1-phosphate (Man1P), and cognate acceptor, 
glucose, in the production of b-D-mannopyranosyl-(1®3)-D-
glucopyranose (disaccharide 1), (Scheme 1B). Furthermore, we 
used X-ray crystallography in conjunction with STD NMR to 
investigate the interaction between PsLBP and its substrates, in 
orfder to understand structural features that contribute to its donor 
substrate specificity.   
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Scheme 1. Reactions carried out by PsLBP. (A) Glc1P and Glc as a donor and acceptor respectively. (B) Man1P and Glc as a donor and acceptor respective
Results 
Recombinant protein expression and PsLBP activity on the 
native donor and acceptor.  
To obtain recombinant PsLBP protein for in vitro characterisation 
and X-ray crystallography, the gene encoding sequence of PsLBP 
was obtained from GenBank (accession number AB568298.2), 
codon-optimised for E. coli expression and synthesised by Gen9. 
The gene was amplified by PCR and cloned into a PopinF 
expression vector.[48] The recombinant plasmid containing the 
PsLBP gene was introduced into BL21 (DE3) for protein 
expression. His6-tagged recombinant protein was then produced 
and purified by immobilised affinity chromatography, followed by 
gel filtration. The gel filtration trace showed 3 different main peaks 
with different elution times (Figure 1A, peaks a, b and c).  In order 
to investigate whether the 3 main peaks have similar activities, 
the phosphorylase activity of each peak was individually 
characterised in the synthetic direction (Scheme 1A) by 
phosphate release assays. No significant difference in activity 
was observed between these 3 peaks (data not shown) and that 
the enzyme in peak a and b are likely the higher oligomeric forms 
of PsLBP. Therefore, only peak c was used for further 
experiments based on its highest protein yield. SDS-PAGE 
analysis of peak c showed a major band of protein with an 
approximate size of 100 kDa, in agreement with the calculated 
mass of PsLBP monomer (101.6 kDa) (Figure 1B). However, gel 
filtration analysis of peak c against standard proteins showed that 
PsLBP formed a dimer in non-denaturing conditions with an 
estimated molecular mass of 240kDa.  
 
To further confirm that the recombinant PsLBP was active, the 
enzyme was assayed in the synthetic direction (Scheme 1A) in 
the presence of its natural substrates (Glc and Glc1P) and the 
reaction mixture was subjected to HPAEC-PAD analysis. The 
analysis showed that laminaribiose (LB) was produced (Figure 
1C), complemented by the release of inorganic phosphate, which 
could be detected by a phosphate release assay (Figure S1).[35] 
 
 
Figure 1. Expression and characterisation of recombinant PsLBP.  (A) gel 
filtration analysis to determine the size of PsLBP. Elution volume of peak c (64.7 
ml) was used to estimate the mass of the protein from a calibration curve 
constructed from standard proteins with known molecular mass. (B) SDS-PAGE 
analysis of the recombinant protein after IMAC and gel filtration. (C) HPAEC-
PAD analysis of the synthetic reaction carried out by PsLBP when incubated the 
enzyme with 10 mM Glc and 10 mM Glc1P for 30 minutes at 45 ̊C. NE = no 
enzyme control. 
 
Activity towards non-cognate donors.  
PsLBP activity has previously been screened on several non-
cognate acceptors, including mannose, methyl β-glucoside, 2-
deoxyglucose and 6-deoxyglucose, with 50-100 fold reduction in 
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the activity compare to that of Glc.[13] However, the specificity 
towards non-cognate sugar 1-phosphate donors has not been 
reported. To assess the donor specificity of PsLBP, the enzyme 
was assayed in the presence of α-D-galactosamine 1-phosphate 
(GalN1P), α-D-glucosamine 1-phosphate (GlcN1P), α-
galacturonic-acid 1-phosphate (GalA1P), Gal1P or Man1P as 
donors and Glc as an acceptor. TLC and HPAEC-PAD analysis 
of the reactions showed that the enzyme can use Man1P as a 
donor, as indicated by the presence of an additional spot on TLC, 
corresponding to a generation of disaccharide 1 (Figure 2A and 
B). Kinetic parameters for the synthetic reaction using either 
Glc1P or Man1P as donors and Glc as a receptor showed 
comparable KM values for Glc1P and Man1P, while the kcat for 
Glc1P is more than 100-fold higher than that for Man1P (Table 1). 
 
Table 1. Kinetic data of PsLBP for Glc1P and Man1P as donors in the presence 
of 10 mM Glc as an acceptor and for Glc in the presence of 10 mM Glc1P.  
 
 
 
 
 
 
 
A large scale enzymatic reaction was carried out in 5-ml reaction 
containing 700 μg of the enzyme, 10 mM Glc and 20 mM Man1P, 
incubating for 15 hr to produce milligram quantities of 
disaccharide 1 (Figure 2C and S2A). Unreacted Man1P and 
inorganic phosphate by-product were then removed from the 
reaction mixture by anion exchange chromatography and the  
disaccharide 1 was isolated by GPC (Figure S2A). The isolated 
disaccharide 1 was analysed on TLC, which showed that only one 
product was obtained with no Glc contamination (Figure S2B).  
Mass spectrometry analysis of disaccharide 1 on the TLC plate 
showed a major peak with m/z of 364.9, corresponding to mass 
of a disaccharide with sodium adduct (Figure S2C). These data 
are in line with those for reported by Awad et al. for the same 
disaccharide arising from GH130 b-1,3-mannan phosphorylase-
mediated synthesis.[49]  
Assignment of NMR signals of disaccharide 1 (Figure S3 and 
Figure S4) was possible with the use of 2D experiments: COSY 
(Figure S5), HSQC (Figure S6) and 2D non-decoupled HSQC 
(Figure S7), as well as literature data for model methyl β-
mannoside (Table S1).[50] Assignment was also helped by 
simulated spectra of disaccharide 1 generated by CASPER 
program (Table S2).[51] Downfield positions of resonances of C-3 
of β-Glc (84.6 ppm) and C-3 of α-Glc (82.1 ppm) residues with 
respect to corresponding signals in D-glucose (73.8 and 77.0 for 
a- and b-anomers respectively) [52] indicated presence of 3-O-
glycosylated glucopyranose unit. Coupled HSQC experiment 
revealed 1JC-H of 163 Hz for anomeric signals of mannopyranose 
residue, the value is characteristic of β-mannopyranosides 
(Figure S7).[52]  Most of carbon signals of the mannosyl residue in 
13C NMR of 1 are split into two very close peaks, due to the 
presence of α/β-anomers of Glc residue (Figure S3). Anomeric 
signals of non-reducing β-Glc residue are expected to appear at 
103-104 ppm [50,53] but there are no peaks in that region, therefore 
presence β-glucosides can be excluded. By comparison with the 
previously reported Glc-b-1,3-Glc 13C NMR spectral,[54] signals at 
95.7 and 92.1 ppm can be assigned to C-1 of reducing β-Glc and 
α-Glc moieties respectively, whereas signals at 84.6 and 82.1 
ppm can be assigned to C-3 β-Glc and C-3 α-Glc respectively.  
 
Overall crystal structures of PsLBP  
Three PsLBP structures were determined and designated 
according to the ligands found in their active sites; SO42- complex, 
Glc1P complex and Man1P complex. All structures belong to the 
same space group (P41212) and contain two subunits per 
asymmetric unit, which are related by a non-crystallographic 2- 
fold axis that superposes them with an R.M.S.D of 0.651 Å. The 
two copies of the molecule in the asymmetric unit formed a 
biological homodimer with an interfacial area of ~3360 Å2 as 
calculated by jsPISA.[55] The formation of homodimer observed in 
crystal structures is in agreement with the gel filtration analysis, 
where PsLBP was eluted as a dimer. Other GH94 enzymes also 
form homodimer with the exception to LpSOGP which is the only 
reported monomeric GH94.   
 
Each PsLBP monomer consists of 4 domains (Figure 3A and B), 
which are an N-terminal β-sandwich (residues 1-297; yellow), a 
helical linker region (residues 298-327; lilac), an (α/α)6 catalytic 
domain (residues 328-808; green) and a C-terminal domain 
(residues 809-911; red). The domain organisation in PsLBP is 
similar to that observed in other GH94 disaccharide 
phosphorylases, which include cellobiose phosphorylases from 
Cellomonas uda (CuCBP),[56] CgCBP,[27] chitobiose 
phosphorylase from Vibrio proteolyticus (VpCBP) [29] and 
cellobionic acid phosphorylase from Saccharophagus degradans 
Donors kcat (s-1) KM (mM) kcat/KM       
(s-1mM-1) 
Glc1P 13.0 ± 1.4 4.20 ± 1.5 3.07 
Man1P 0.08 ± 0.01 3.80 ± 1.0 0.02 
Glc 15.4 ± 1.3 6.04 ± 1.3 2.55 
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(SdCBAP).[57] PsLBP lacks the extended N-terminal α/β domain 
(Figure 3B, purple) that is only present in GH94 oligosaccharide 
phosphorylases including cellodextrin phosphorylase from 
Ruminoclostridium thermocellum (RtCDP) [30] and LpSOGP.[31]  
The role of the extended N-terminal domain in RtCDP was 
proposed to be involved in the interaction of the lower portions of 
the homodimer, causing the upper portions to move apart, which 
leads to a widening of the active site to accommodate a larger 
acceptor (i.e. cellodextrin) in RtCDP.[30]  
 
Phosphate recognition by PsLBP 
In the SO42- complex (Figure S9A), SO42- which was derived from 
the precipitant used for crystallization, occupied a similar position 
to phosphate and sulphate in other GH94 disaccharide 
phosphorylases such as in CgCBP (Figure S9B).   The SO42- 
molecule forms hydrogen bonds with R353, T731 and E782 side 
chains. From the amino acid sequence alignment of PsLBP, 
CgCBP and RtCDP, H739 in PsLBP aligned with the conserved 
histidine residues in CgCBP and RtCDP that forms a hydrogen 
bond with phosphate in the active site (Figure S9B). However, the 
distance between H739 side chain and SO42- in PsLBP structure 
is greater than hydrogen bonding distance, suggesting that H739 
may not be essential for phosphate recognition. This is further 
supported by three evidences.  Firstly, when the corresponding 
histidine (H666) in CgCBP was mutated to Asn, a phosphate 
molecule still bound to the active site of the enzyme (PDB code 
3ACT). Secondly, the phosphate moiety in Glc1P in complex with 
LpSOGP does not form hydrogen bond with the corresponding 
histidine (H924) (Figure 4B).[31] Lastly, a wild-type cellodextrin 
phosphorylase from Ruminococcus albus has Gln646 instead of 
the conserved His residue that is found in other GH94 
phosphorylases.[58]  
 
Glc1P and Man1P recognition by PsLBP  
The overall structure of SO42- complex and Glc1P complex are 
very similar (R.M.S.D of 0.23 Å for a dimer on dimer 
superposition). Glc1P was bound with the pyranose ring in 4C1 
conformation and α-anomeric configuration of phosphate at C1 
position, supporting the enzyme specificity for sugar 1-phosphate 
in a-anomeric configuration. Glc1P is completely buried within a 
donor subsite (-1 subsite), which is formed entirely within a single 
subunit of PsLBP. Comparison between Glc1P complex of PsLBP 
with that of LpSOGP (Figure 4B, PDB code 5H42) showed that 
Glc1P recognition by the two proteins is different. In PsLBP, the 
hydroxyl group on C3 form a hydrogen bond with R374 side chain 
(Figure 4A), whereas in LpSOGP, the same hydroxyl group forms 
hydrogen bonds with R630 and D631. In LpSOGP structure, D631 
also involves in the recognition of the hydroxyl group on C2 via 
hydrogen bonding, whereas in PsLBP, the hydroxyl group forms 
hydrogen bond with R353. The equivalence of D631 in PsLBP 
(D375) form hydrogen bond with neither the hydroxyl groups on 
C2 or C3 because the distance between the hydroxyl groups on 
C2 and C3 and D375 is greater than the hydrogen bonding 
distance. The phosphate moiety in Glc1P also interact differently 
with the enzyme active sites. In PsLBP, the phosphate moiety 
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Figure 2. PsLBP activity on Man1P and production of disaccharide 1. (A) Screening of the synthetic activity of PsLBP (8 µg) on 4 different donors (10 mM) in 
the presence of 10 mM Glc as an acceptor. The reactions were incubated at 45 ̊C for 30 minutes. (B) HPAEC-PAD analysis of the reaction containing Glc and 
Man1P as substrates. (C) TLC analysis of the Glc + Man1P large scale reaction at time intervals.
forms hydrogen bonds with the side chains of R353 and E782, 
similar to those found in SO42- complex, whereas in LpSOGP, the 
phosphate moiety in Glc1P forms hydrogen bonds with S1005 
and Y922.  
 
The Man1P complex (Figure 4C) represents the first GP structure 
in complex with a non-cognate sugar 1-phosphate donor. The 
overall structure of Glc1P complex and Man1P complex are very 
similar (R.M.S.D of 0.14 Å for a dimer to dimer superposition). 
Man1P position almost overlaps completely with that of Glc1P, 
suggesting similar binding mode to Glc1P. However, the 
hydrogen bond between axial hydroxyl group on C2 and R353 
side chain cannot form since the distance between the hydroxyl 
group on C2 and R353 side chain is 5.1 Å (in contrast to 3.2 Å 
between the equatorial hydroxyl group on C2 and R353 in Glc1P 
complex). The loss of hydrogen bond between C2-hydroxyl group 
and R353 side chain in Man1P complex may have a negative 
impact on the conversion of Man1P and Glc to disaccharide 1, 
which is reflected in the reduction in kcat/Km from 3.07 (when 
Glc1P was used as a donor) to 0.02 (when Man1P was used) that 
were previously observed in the kinetic studies.  
 
Figure 3. Structural comparison between CgCBP,  RtCDP and PsLBP. (A) Comparison between the GH94 structures. All proteins are in dimeric form. The 
domains are coloured in one subunit only, while the other subunit is coloured in grey. Green spheres represent ligands bound in the active sites.  (B) Sequences of 
RtCDP, PsLBP and CgCBP coloured according to the domains. (C) Summary of conserved residues found in the amino acid sequence alignment of CgCBP, PsLBP 
and RtCDP. The conserved residues are involved in Glc1P binding (blue), phosphate binding (magenta) or the predicted catalytic aspartate (red). Detail of the 
alignment can be found in Figure S8. 
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Figure 4. Comparison between PsLBP (A) and LpSOGP (B) in complex with Glc1P. (C) The active site of PsLBP in complex with Man1P. The C2 position 
on the pyranose ring is indicated with black arrow head. The protein backbone is shown in cartoon representation and the neighbouring side chains in stick 
representation. The conserved catalytic loop is presented in purple. The catalytic residue (D526) is underlined.  
Catalytic loop in GH94 enzymes 
The catalytic loop (purple, Figure 4) is a highly conserved feature 
among GH94 structures. In PsLBP, this loop consists of WND 
motif (W524, N525 and D526), with D526 as a predicted catalytic 
residue. The tryptophan residue (W524) is structurally conserved 
among GH94 members and provides a hydrophobic platform for 
the binding of the donor.[30]  Comparison between the CgCBP and 
PsLBP structures showed that the PsLBP active site is slightly 
more closed in comparison to CgCBP due to several different 
structural features. Firstly, the length of the PsLBP catalytic loop 
is 10-amino acid residues shorter than that of CBP, and only 
partially occludes the active site. In contrast, the extended 
catalytic loop in CgCBP forms a lid-like structure that extends over 
the active site (Figure S10A and B, purple). Secondly, the position 
of the ‘adjacent loop’ (Figure S10A and B, brown) runs in parallel 
to a significant proportion of catalytic loop in CBP, forming a 
zipper-like interface that further encloses the CgCBP active site.  
The absence of the extended catalytic loop in PsLBP may be 
compensated for the presence of a loop in the β-sandwich domain 
of the opposing subunit, which is six residues longer than the 
equivalent loop in CgCBP. This forms a β-hairpin ‘gate’ loop, 
which overlaps with the extended catalytic loop in CgCBP (Figure 
S10BC and D, cyan). 
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Moreover, the opposing loop in CgCBP projects into the active 
site more than that of PsLBP (Figure S10, red). Whereas in 
PsLBP, the active site is relatively open, since the opposing and 
adjacent loops are located further away from the active site with 
respect to those in the CgCBP structure. The relatively “open” 
state of the PsLBP active site may be representative of the initial 
binding of the sugar 1-phosphate donor before the synthetic 
reaction occurs or the final stage of phosphorolysis where sugar 
1-phosphate is about to be released. On the other hand, the 
relatively “closed” state observed in CgCBP structure likely 
represents the intermediate state of the catalysis where the 
glycosidic bond is either being broken during phosphorolysis or 
being formed during the synthetic reaction.  
 
STD NMR and CORCEMA-ST suggests different binding 
affinity of Glc1P and Man1P to PsLBP 
To study to the interaction between PsLBP and Glc1P or Man1P, 
binding epitopes for Glc1P and Man1P were constructed (Figure 
5A and B) using the initial rates approach (SI 1) to avoid 
overestimation of slow relaxing protons at large saturation times 
and to eliminate any effect of ligand rebinding.[59] The epitope 
maps provide a qualitative measure of proximity of the protons of 
the ligands to the protein surface, with larger values indicating 
more intimate contact.[38]  
 
For Glc1P (Figure 5A) all the ligand protons received strong 
saturation from the protein indicating that the sugar is intimately 
recognised making contacts all along the ring. Nevertheless, the 
exocyclic H6 protons exhibit the strongest STD intensities, 
followed by H4, whilst H1 and H2 exhibit the weakest STD 
intensities (Table S3). This suggests that the H4/H6 area is buried 
within the binding cavity, whilst the H1/H2 is further from it, and 
most likely being more exposed to the solvent. This is in very good 
agreement with the X-ray structure (Figure 4A) and with the role 
of Glc1P as a donor substrate, since an open cavity exists 
adjacent to the anomeric proton in order to accommodate the 
acceptor substrate.  
 
The binding epitope of Man1P (Figure 5B) follows a similar 
ranking as seen for Glc1P, suggesting that Man1P binds to the 
same subsite as Glc1P, with a rather similar binding mode. This 
is in agreement with the X-ray structure (Figure 4C) and the 
observation that Man1P can act as donor substrate. Importantly, 
the larger dispersion of STD values observed for Man1P, 
compared to Glc1P, is an indicative of a shorter residence time, 
and therefore weaker affinity of Man1P. Since the only difference 
between the two substrates is the configuration at C2, it follows 
that a favourable interaction, observed for the native Glc1P, is 
broken by the inversion in Man1P.  
 
 
Figure 5. STD NMR experiments on Glc1P and Man1P. (A) Binding epitope 
of Glc1P in the presence of PsLBP. (B) Binding epitope of Man1P in the 
presence of PsLBP. Colours represent normalised values of STD0 at each 
position depicted in the structure. For each ligand, the values of STD0 are 
normalised against the largest value (see Table S3 for the normalised STD0). 
(C) Experimentally determined STD build-up curves for Glc1P binding to PsLBP 
(top) and CORCEMA-ST-calculated STD intensities (bottom). The NOE R-
factor (RNOE) between the experimental and calculated data is 0.09. (D) 
Experimentally determined STD build-up curves for Man1P binding to PsLBP 
(top) and CORCEMA-ST-calculated STD intensities (bottom). The NOE R-
factor between the experimental and calculated data is 0.23. For experimental 
data, circles show observed STD intensities, whilst curves are determined from 
least squares fitting to the equation in SI 1.   
 
CORCEMA-ST [60] can be used to predict STD intensities based 
on a three-dimensional model of the protein-ligand complex, e.g. 
derived from X-ray crystallography, NMR spectroscopy, or 
molecular modelling. These intensities can then be compared 
against experimental STDs to determine whether the model of the 
complex is able to quantitatively explain the experimental STD 
NMR data. This comparison is carried out using the so-called 
NOE R-factor (RNOE) (SI 2).[61] Generally, a RNOE of less than 
0.3 is considered a good fit to the data.  
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For the crystal structure of the Glc1P complex (vide supra), the 
RNOE was 0.09 (Figure 5C), indicating an excellent fit between 
the crystal-derived model complex and the solution-state complex 
observed by NMR. For the crystal structure of the Man1P complex, 
the RNOE was 0.23 (Figure 5D). The poorer, yet still very good, 
fit indicates a less well-defined binding mode in solution, given the 
lower affinity. 
 
STD NMR identified the binding subsite for Glc and the 
directional binding of LB and disaccharide 1 to PsLBP 
In the study of Glc binding, the exchange between its α- and β-
anomers precluded such a detailed study, due to the combination 
of different concentrations of the species and the significant peak 
overlap observed from both anomers. However, it is clear from 
the spectra that although similar concentrations of each anomer 
are present, the STD intensities from the α-anomer are very much 
weaker than those from the β-anomer (Figure 6A and C and S11). 
This indicates that the β-anomer is preferentially recognised by 
the enzyme. This suggests several things. Firstly, the subsite 
occupied by Glc1P and Man1P must require a sugar 1-phosphate, 
otherwise it would be expected that α-Glc would bind well. This 
then means that Glc must bind to a separate subsite, in 
agreement with its role as the acceptor substrate. Finally, the 
structure of this subsite must be such that α-Glc, with its axial C1-
hydroxyl group, is unable to bind, perhaps due to steric 
interactions. 
 
As in Glc, the reducing end of LB exists as an equilibrium between 
both of its α- and β-anomers. Again, it is observed that the β-
anomer is preferentially recognised by the enzyme (Figure 6B and 
S12). Given the proposed reaction mechanism and the polarity of 
the disaccharide, it appears that the non-reducing ring of LB 
(Glc1) binds to the same subsite as Glc1P/Man1P, whilst the 
corresponding reducing sugar (Glc2β) binds to the same subsite 
as Glc. The saturation transferred to the reducing end of LB 
(Figure 6D, bottom) is much stronger than that received by the 
non-reducing ring (Figure 6D, top), suggesting that the key 
interaction between the ligand and the enzyme is formed with the 
reducing sugar hexopyranose moiety. This agrees with the 
previous observation that the -1 subsite can only recognise sugar 
1-phosphates effectively. 
 
 
 
Figure 6. STD NMR experiments on Glc and LB. (A) Binding epitope of Glc(β) 
in the presence of PsLBP. (B) Binding epitope of LB(β) in the presence of 
PsLBP. Colours represent normalised values of STD0 at each position depicted 
in the structure. For each ligand, the values of STD0 are normalised against the 
largest value (see Table S3 for the normalised STD0). (C) Experimentally 
determined STD build-up curves for Glc(β) binding to PsLBP. (D) 
Experimentally determined STD build-up curves for LB(β) binding to PsLBP. 
Circles show observed STD intensities, whilst curves are determined from least 
squares fitting to the equation in SI 1.   
 
STD NMR was also performed on disaccharide 1 and PsLBP to 
determine the interaction between the non-cognate product and 
the protein. Overall interaction between PsLBP and disaccharide 
1 is similar to that described in LB, with the main contacts 
appearing to be with Glc2, in particular with the H6’s as previously 
mentioned for LB (Figure 7A and 7B). The magnitude of the STD 
intensities is comparable to those of LB, suggesting the affinity is 
similar. This would make sense given that the Glc2, common to 
both, seems to be the most important for recognition. Moreover, 
only the β-anomer binds strongly to PsLBP, with the STD 
intensities for the α-anomer being very much weaker (Figure 7C). 
However, the STDs for the H6 of Man1 are a lot stronger than in 
Glc1 in LB. This may be because Man binds in a slightly different 
orientation, which is probably to be expected given the different 
stereochemistry of the C2.  
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Figure 7. STD NMR experiments on disaccharide 1. (A) Binding epitope of 
disaccharide 1(β) in the presence of PsLBP. Colours represent normalised 
values of STD0 at each position depicted in the structure. For each ligand, the 
values of STD0 are normalised against the largest value (see Table S3 for the 
normalised STD0). (B) Experimentally determined STD build-up curves for 
Man1 binding to PsLBP. (C) Experimentally determined STD build-up curves for 
Glc2β and Glc2α in disaccharide 1 binding to PsLBP. Circles show observed 
STD intensities, whilst curves are determined from least squares fitting to the 
equation in SI 1. 
 
Discussion  
GPs are attractive biocatalyst for oligo- and polysaccharides 
synthesis due to their broad speficity towards acceptor substrates 
and relatively low cost of donors compared to other enzymatic 
glycan syntheses. Understanding the mechanism of GP action on 
both natural and non-cognate substrates would therefore provide 
background knowledge that would underpin applications of GPs 
in carbohydrate synthesis, both in academic and industrial 
settings. Unlike other conventional substrate screening 
experiments which have been conducted by various groups on 
GPs, [13–15,26,30,35,49,62,63] we aimed to pinpoint the mechanism by 
which PsLBP recognised and utilised Man1P as its non-cognate 
donor, using X-ray crystallography and STD NMR spectroscopy.  
 
The use of GPs for β-1,3-mannosylation has been previously 
conducted using a GH130 b-1,3-mannan mannoside 
phosphorylase (Zg0232) from Zobellia galactanivorans DSM 
12802, which transfers mannose from Man1P to a variety of sugar 
acceptors, including a non-cognate acceptor, Glc.[64] In contrast, 
our study demonstrates the relaxed specificity of PsLBP towards 
the sugar 1-phosphate donor, Man1P, from which mannose was 
transferred onto a Glc acceptor, resulting in the production of 
Man-β-1,3-Glc disaccharide 1. 
 
Significant interactions between Glc1P and PsLBP, as indicated 
by the crystal structure and STD NMR analysis, suggests that the 
specificity of this enzyme towards the donor substrate is more 
restricted compared to the acceptor site. Therefore, any 
manipulation to broaden the donor specificity may be challenging. 
Nevertheless, our work demonstrated a relaxed specificity of 
PsLBP towards Man1P, which indicates that alternative 
configurations of the hydroxyl group at C2 on the pyranose ring 
are tolerated. A strengthening of the interaction of Man1P with the 
active site could be the strategy to make the production of 
disaccharide 1 more efficient. However, the enzyme crystal 
structure showed that the axial configuration of the C2-OH of 
Man1P is pointing into empty space (at the dimer interface), 
suggesting that a simple mutation approach is unlikely to restore 
a hydrogen bond with C2-OH on Man1P. On the other hand, 
GlcN1P was not a substrate for PsLBP despite having the same 
configuration as Glc1P at C2. In this case, the C2-OH group is 
substituted by an NH2, which likely causes steric and/or 
electrostatic clashes with R353, thus disfavouring the binding of 
GlcN1P to the active site. The size restriction of the substituted 
group at C2 position has been reported in CgCBP, which cannot 
accommodate GlcNAc1P (OH is replaced by CH3CONH at C2), 
whereas VpChBP can accommodate both GlcNAc1P and Glc1P, 
despite having the same amino acid for interaction with the 
hydroxyl group at C2.[17] The difference is only in the placement 
of the Arg side chain that interacts with the C2 group, which is 
more distant in VpChBP to accommodate a larger substitution.[27]  
 
Crystallographic structures and STD NMR data generated in this 
study enabled us to explain the PsLBP preference for other sugar 
1-phosphates (see Figure S13 for structures of all sugar 1-
phosphate mentioned in discussion below). For instance, a 
hydrogen bond formed between C4-OH and the side chains of 
R374 and the strong saturation transfer signal from the protein to 
the hydrogen on C4 in the STD NMR experiment indicate that C4-
OH and its configuration might be crucial for the recognition of 
Glc1P by PsLBP and therefore any modification at this position 
may compromise the enzyme activity on the donor. This 
hypothesis is supported by the fact that PsLBP could not use 
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Gal1P as a sugar donor (Figure 2A TLC enzyme screening), 
which has the C4-OH in an axial rather than equatorial position. 
The same explanation can be used to explain the lack of PsLBP 
activity towards GalN1P and GalU1P, both of which are 
derivatives of Gal1P. We can also predict whether PsLBP can 
work on donors that we have not screened in this work. For 
instance, glucuronic-acid 1-phosphate (GlcU1P) which has 
carboxyl group substitution at C6 would likely cause steric and 
electrostatic clashes with E732 and therefore may not permit 
binding of GlcU1P to PsLBP. The importance of C6 for binding to 
PsLBP was evident from the strong STD intensities at the 
germinal protons at this position in both Glc1P and Man1P. 
 
Both PsLBP and CBPs work on disaccharides, but with different 
linkage specificity (i.e. b-1,3 vs b-1,4). However, each enzyme 
may employ a different mechanism to restrict the length of the 
substrate/product. In CgCBP, the extended catalytic loop is a 
unique characteristic to CgCBP that was not found in our PsLBP 
structure, nor in any other characterised disaccharide 
phosphorylases in GH94 family. It is likely to be involved in the 
substrate specificity of CgCBP with regards to the degree of 
polymerisation of the product.[27] In contrast, PsLBP contains a 
unique β-hairpin ‘gate’, which when superposed with the CBP 
structure, overlaps with the position of the extended catalytic loop 
of the latter. Therefore, the β-hairpin gate in PsLBP may perform 
similar role to that of the CgCBP extended catalytic loop in 
restricting the degree of polymerization.  
 
In summary, we have demonstrated the simple enzymatic 
synthesis of a non-natural disaccharide by utilising the 
promiscuity toward non-cognate sugar 1-phosphates of PsLBP 
and provide structural insight into the mechanisms whereby the 
enzyme distinguishes sugar 1-phosphate donors. Our work 
provides a stepping stone towards the design and engineering of 
GPs for tolerance towards other non-cognate sugar donors, which 
will help to expand the range of GP applications in carbohydrate 
synthesis.  
 
Experimental section 
Expression and purification of PsLBP: The PsLBP cDNA sequence was 
synthesized and optimized for E. coli expression (custom DNA synthesis 
by Gen9, Inc.). The sequence was amplified by PCR and cloned into the 
PopinF plasmid vector [48] using In-Fusion™ (TakaraBio, Mountain View, 
CA, USA) following the manufacturer’s protocol. The recombinant PopinF-
PsLBP was transformed into E. coli (BL21 (DE3)) and a one l culture of the 
transformant was grown at 37 °C in LB media with agitation (180 rpm) until 
OD600 ~0.7.  Heterologous protein expression was induced by adding IPTG 
to a final concentration of 0.2 mM and incubated overnight at 18 °C. The 
cells were harvested (6721 x g, 10 min) and lysed by sonication in buffer 
A (20 mM HEPES pH 7.0, 250 mM NaCl) supplemented with DNase (1 
mg/ml, Sigma). Supernatant containing the recombinant proteins was 
separated from cell debris by centrifugation (32,914 x g, 30 min), then 
purified with an ÄKTA pure FPLC system (GE Healthcare) at 4 °C. The 
supernatant containing His6-tagged PsLBPwas loaded to a 1-ml HisTrapTM 
HP column (GE Healthcare) pre-equilibrated with buffer A (10 mM HEPES 
pH 7.5, 250 mM NaCl). The column was washed with buffer A and bound 
proteins was eluted in one step with 10 mM HEPES pH 7.5, 250 mM NaCl, 
500 mM imidazole. The sample was further purified by gel filtration using 
a Superdex S200 16/600 column (GE Healthcare) eluted with 20 mM 
HEPES pH 7.5, 150 mM NaCl, 1 ml/min. Fractions containing the proteins 
were pooled and concentrated to 10 mg/ml using Amicon Ultra-15 30 kDa 
MW cut off concentrator. The protein was stored in 30 µl aliquots at -80 °C 
until required. To estimate the assembly of PsLBP in solution, a calibration 
curve was generated using standard proteins from Gel Filtration 
Calibration Kit HMW (GE Healthcare). Approximately 2 mg/ml of the 
standard proteins were analysed individually using the same method 
described for PsLBP to determine the elution volumes. These values were 
then used to construct a calibration curve, following the manufacturer‘s 
protocol.  
Enzymatic assays: Phosphate release assay [35] was carried out in an 
assay buffer (20 µl, 100 mM HEPES pH 7.0, 20 mM sugar 1-phosphate 
donors, 10 mM acceptors, 200 mM sodium molybdate) . The reactions 
were incubated at 45 °C for 30 minutes.  A color solution (90 µl, 0.1 M HCl, 
13.6 M sodium ascorbate) was added to the boiled reaction mixture and 
incubated for 30 minutes at room temperature to allow color development. 
A stop solution (90 µl, 68 mM sodium citrate tribasic dihydrate, 2% acetic 
acid) was added to the mixture to stop the color development. The 
absorbance of final solution was measured at 620 nm on a 96-well plate 
reader. The amount of phosphate release was calculated from the 
absorbance by comparing to a phosphate standard curve ranging between 
0-10 mM. All assays were performed in triplicates. Kinetic parameters of 
PsLBP were determined using the phosphate release assay (20 µl) with 
the enzymes (25 µg/ml) in the presence of 0.2-10 mM of Glc and 10 mM 
Glc1P or Man1P. The amount of phosphate release from the assays were 
measured and the values were fitted on non-linear regression with 
Michaelis-Menten model using GraphPad Prism to determine Vmax and Km. 
Oligosaccharide analysis: TLC was performed by spotting the recovered 
reaction mixture (0.5 μl) onto a silica plate (10 cm x 5 cm), then eluted 
using a mobile phase containing NH4OH : H2O : iso-propanol (3:1:4) in a 
sealed glass container for 2 hour to allow oligosaccharide separation.  The 
plate was air-dried and stained with orcinol, which was prepared by adding 
concentrated sulfuric acid (20 ml) to ice cold solution of 3,5-
dihydroxytoluene (360 mg) in ethanol (150 ml) and water (10 ml). The 
stained plate was then heated until oligosaccharide spots were visible.  
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HPAEC-PAD analyses were performed by diluting the reaction mixtures in 
MilliQ water to a final volume of 500 μl and desalted by mixed bed ion 
exchange resin (Sigma). The desalted mixtures were filtered through a 
disposable PTFE 0.45 μm filter disc (Merck Millipore), and subjected to 
HPAEC-PAD analysis using a Dionex ICS3000 chromatography system 
equipped with PAD and controlled by Chromeleon® software. A PA100 
CarboPac column (analytical: 4 x 250 mm, guard: 4 x 50 mm) was used 
for all analyses. The solutions for elution of the oligosaccharides were as 
follows; solution A: 100 mM sodium hydroxide and solution B: 100 mM 
sodium hydroxide + 400 mM sodium acetate. The separation was 
achieved by gradient elution (0-100% solution B) from 1-30 min, followed 
by 30-50 min of 100% B then 50-60 min re-equilibration of the column with 
solution A. The solutions were delivered to the column at the rate of 0.25 
ml/min.  
NMR spectroscpy. 1H NMR were recorded at 298 K on a Bruker at 800 
MHz and 13C NMR were recorded at 298 K on a Bruker Avance III 400 
spectrometer at 100 MHz. Chemical shifts (δ) are reported in parts per 
million (ppm) with respect to residual HOD signal in D2O (δH 4.79). 
Coupling constants (J) are reported in Hz. NMR signal assignments were 
made with the aid of COSY and HSQC experiments. 
Mass spectrometry: disaccharide 1 was analysed by spotting 1 µl of 2 
mg/ml in water onto a silica gel plate. The spot was analysed by TLC/MS 
(Plate Express™, Advion BioSciences, Ithaca, NY, USA), which subjects 
the compound to electrospray ionisation using spray voltage and sample 
delivery pressure of 3.5 kV and 3,000 psi for positive ion mode, with the 
flow rate of 0.3 ml/min. The sample was analysed at the capillary 
temperature of 250 ̊C, collision energy and the scan time of 1799 ms. 
Optical rotation analysis: disaccharide 1 was dissolved in water to the 
final concentration of 2.2 mg/ml. The specific rotation of disaccharide 1 
was recorded on a polarimeter model 341 polarimeter (PerkinElmer) at 
20 ̊C, 589 nm.  
Physical data for b-D-mannopyranosyl-(1®3)-D-glucopyranose 
(disaccharide 1): [α]D20  +7° (c 0.2, H2O); 1H NMR (800 MHz, D2O) δ 5.172 
(d, J=3.7, 1H, H-1 α-Glc), 4.839 (d, J=1.1, 1H, H-1 β-Man), 4.823 (d, J=1.0, 
1H, H-1 β-Man), 4.611 (d, J=8.1, 1H, H-1 β-Glc), 4.081 – 4.049 (m, 2H, H-
2 β-Man), 3.897 – 3.851 (m, 2H, H-6 β-Man), 3.865 – 3.808 (m, 2H, H-3 α-
Glc, H-6 β-Glc), 3.801 (dddd, J=10.0,  5.0, 2.3, 0.6, 1H, H-5 α-Glc), 3.772 
(dd, J=12.3, 2.3, 1H, H-6 α-Glc), 3.718 (dd, J=12.3, 5.0, 1H, H-6’ α-Glc), 
3.698 – 3.642 (m, 4H, H-6 β-Man, H-3 β-Glc, H-6’ β-Glc), 3.633 – 3.579 
(m, 3H, H-3 Man, H-2 α-Glc), 3.527 (t, J=9.7, 1H, H-4 β-Man), 3.522 (t, 
J=9.7, 1H, H-4 β-Man), 3.491 – 3.454 (m, 2H, H-4 α-Glc, H-4 β-Glc), 3.429 
(ddd, J=10.0, 5.5, 2.2, 1H, H-5 β-Glc), 3.374 – 3.334 (m, 2H, H-5 β-Man), 
3.314 (dd, J=9.3, 8.1, 1H, H-2 β-Glc); 13C NMR (101 MHz, D2O) δ 100.56 
and 100.51 C-1 Man), 95.7 (C-1 β-Glc), 92.1 (C-1 α-Glc), 84.6 (C-3 β-Glc), 
82.1 (C-3 α-Glc), 76.35 and 76.31 (C-5 Man), 75.4 (C-5 β-Glc), 73.7 (C-2 
β-Glc), 72.9 and 72.8 (C-3 Man), 71.1 (C-5 α-Glc), 70.9 (C-2 α-Glc, 70.5 
(C-2 Man), 68.2 and 68.1 (C-4 α-Glc and C-4 β-Glc), 66.7 (C-4 Man), 61.0 
(C-6 Man), 60.7, 60.53 (C-6 Glc); HRMS (ESI): calculated for 
C12H22NaO11+ m/z 365.1054, found m/z 365.1062. 
Crystallographic methods: Crystallization trials were set up for purified 
PsLBP (~10 mg/ml in 20 mM HEPES pH 7.0, 150 mM NaCl) using a range 
of commercial crystallisation screens (Molecular Dimensions) in MRC2 96-
well sitting-drop vapour diffusion crystallization plates (Swissci) with a 
mixture of 0.3 µl well solution and 0.3 µl protein solution using an 
OryxNano robot (Douglas Instruments). After optimisation, the best 
crystals were obtained from drops containing 0.4 µl of protein and 0.2 µl of 
a crystallisation solution comprised of 18% (w/v) polyethylene glycol 3350, 
0.1 M Tris-citrate buffer pH 6.0, 0.3 M ammonium sulphate. Crystals were 
cryo-protected with well solution containing 20% (v/v) ethylene glycol and 
flash-cooled in liquid nitrogen. For phasing, crystals were soaked for 30 
minutes in a saturated solution of mercury(II) chloride made up in the 
cryoprotectant solution; the ligand bound complexes were obtained by 
soaking crystals for 5 minutes in cryoprotectant containing 20 mM of the 
compound (Glc1P or Man1P).  
The pre-cooled crystals were transferred robotically to the goniostat on 
either beamline I03 or I04 at Diamond Light Source (Oxfordshire, UK) and 
maintained at -173°C with a Cryojet cryocooler (Oxford Instruments). X-
ray diffraction data were recorded using a Pilatus 6M hybrid photon 
counting detector (Dectris), then integrated and scaled using XDS [65]via 
the XIA2 expert system[66]  and merged using AIMLESS [67] All crystals 
belonged to space group P41212 with approximate cell parameters of a = 
b = 147 Å, c = 222 Å (see Table S4 for a summary of data collection 
statistics).  
Analysis of the likely composition of the asymmetric unit (ASU) suggested 
that it would contain two copies of the 102 kDa protein chain, giving an 
estimated solvent content of 58%. The structure was solved at 2.9 Å 
resolution by SAD phasing using the CRANK2 pipeline [68] by combining 
data collected from two mercury soaked crystals at the LIII X-ray absorption 
edge of mercury (wavelength = 1.0052 Å). SHELXD [69] located eleven 
sites in the ASU with occupancies >0.25 and BUCCANEER [70] went on to 
build a model in which 59% of the sequence was fitted with Rwork and Rfree 
values of 0.342 and 0.400, respectively. This was then edited in COOT [71] 
before refining in REFMAC5 [72] against native data processed to 1.95 Å 
resolution. Phases calculated from this model were used as input to 
second BUCCANEER job, which produced a model with 97% of the 
sequence fitted and Rwork and Rfree values of 0.282 and 0.323, respectively. 
The model was finalised by further iterations of manual rebuilding in COOT 
and restrained refinement in REFMAC5 using isotropic thermal 
parameters and TLS group definitions obtained from the TLSMD server 
(http://skuld.bmsc.washington.edu/~tlsmd/).[73] In each of the expected 
active sites, residual density consistent with an oxyanion was present. This 
was interpreted as sulphate derived from the precipitant solution. This 
sulphate-bound structure was used as the starting model for the Glc1P and 
Man1P complexes, which were built and refined as above.  
The geometries of the final models were validated with MOLPROBITY [74] 
before submission to the Protein Data Bank (see Table S4 for a summary 
of model statistics). Omit mFobs-dFcalc difference electron density maps 
were generated for the bound ligands using phases from the final model 
without the ligands after the application of small random shifts to the atomic 
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coordinates, re-setting temperature factors, and re-refining to convergence 
(Figure S14). All structural figures were prepared using CCP4MG.[75] 
STD- NMR: All samples were prepared in D2O with 25mM Tris-d11 pH 7.4 
and contained final protein and ligand concentrations of 50 μM and 6 mM 
respectively. All experiments were performed at 278 K on a Bruker Avance 
III 800 MHz spectrometer equipped with a 5-mm TXI 800 MHz H-C/N-D-
05 Z BTO probe. STD NMR experiments were performed using a train of 
50 ms Gaussian pulses applied on the f2 channel at either 0.8 ppm (on-
resonance) or 40 ppm (off resonance). A spoil sequence was used to 
destroy unwanted magnetisation and a spinlock was used to suppress 
protein signals (stddiff.3). The recycle delay (d1) was set to 5 s. The total 
saturation time and number of scans were selected according to the 
following scheme: 
Total 
Saturation 
Time (s) 
0.5 0.75 1 1.5 2 3 5 
No. Scans 512 512 256 256 128 128 128 
Preparation of models: Crystal structures were imported into 
Schrödinger Maestro [76]  and prepared with the Protein Preparation Wizard. 
All non-protein or non-ligand atoms were removed. Protons were then 
added to the model, using PROPKA to predict the protonation state of 
polar sidechains at pH 7.[77] The hydrogen-bonding network was 
automatically optimised by allowing asparagine, glutamine and histidine 
sidechains to be flipped. The model was then minimised using the 
OPLS3[78] force field and a heavy atom convergence threshold of 0.3 Å. 
Since STD NMR experiments were performed in D2O, polar protons were 
removed from the ligand prior to CORCEMA-ST.[60] 
CORCEMA-ST Calculations: Protein chemical shifts were calculated 
using the SHIFTX2 [79] webserver according to experimental conditions. All 
protein protons within 15 Å of the ligand were considered in the calculation. 
The instrument field strength, solvent type, ligand concentration, and 
protein concentration were set according to experimental values. The free 
and bound ligand correlation times were estimated to be 0.3 ns and 300 
ns respectively, based on reasonable values for a monosaccharide binding 
to a 200 kDa protein. The non-specific leakage was also optimised to 0.8 
s-1. The internal correlation time was set to 10 ps and the methyl-X order 
parameter was set to 0.85, according to previously published values.[60] All 
protein protons with resonances between 0.6 – 1 ppm were considered to 
be instantaneously saturated to account for line broadening. For glucose 
1-phosphate, the equilibrium constant and kon were optimised to 25000 M-
1 and 105 M-1 s-1 respectively. For Man1P, the equilibrium constant was 
reduced to 16000 M-1. Both values are in agreement with the affinities 
typically observed for carbohydrate-binding proteins. 
 
Acknowledgements 
This work was supported by the UK BBSRC Institute Strategic 
Program on Understanding and Exploiting Metabolism (MET) 
[BB/J004561/1]; the UK BBSRC, EPSRC and InnovateUK: 
IBCatalyst [BB/M02903411]; the John Innes Foundation and the 
Royal Thai Government Scholarship program. J. A. and S. W. 
acknowledge funding from the BSRC through a research grant 
(BB/P010660/1) and a DTP PhD studentship, respectively. We 
acknowledge the Diamond Light Source for access to beamlines 
I03 and I04 under proposal MX13467 with support from the 
European Community's Seventh Framework Program 
(FP7/2007–2013) under Grant Agreement 283570 (BioStruct-X). 
 
Keywords: laminaribiose phosphorylase • enzymatic synthesis • 
structural biology • glycosyl hydrolase family 94 
 
[1] V. Puchart, Biotechnol. Adv. 2015, 33, 261–276. 
[2] E. C. O’Neill, R. A. Field, Carbohydr. Res. 2015, 403, 23–37. 
[3] G. Pergolizzi, S. Kuhaudomlarp, R. A. Field, E. Kalita, Protein Pept. 
Lett. 2017, 24, 696–709. 
[4] H. Nakai, M. Kitaoka, B. Svensson, K. Ohtsubo, Curr. Opin. Chem. 
Biol. 2013, 17, 301–309. 
[5] M. Hiraishi, K. Igarashi, S. Kimura, M. Wada, M. Kitaoka, M. 
Samejima, Carbohydr. Res. 2009, 344, 2468–2473. 
[6] Y. Yataka, T. Sawada, T. Serizawa, Langmuir 2016, 32, 10120–
10125. 
[7] T. Nohara, T. Sawada, H. Tanaka, T. Serizawa, J. Biomater. Sci. 
Polym. Ed. 2017, 28, 925–938. 
[8] T. Nohara, T. Sawada, H. Tanaka, T. Serizawa, Langmuir 2016, 32, 
12520–12526. 
[9] C. Goedl, T. Sawangwan, M. Mueller, A. Schwarz, B. Nidetzky, 
Angew. Chemie - Int. Ed. 2008, 47, 10086–10089. 
[10] M. Nishimoto, M. Kitaoka, Biosci. Biotechnol. Biochem. 2007, 71, 
2101–2104. 
[11] K. Beerens, K. De Winter, D. Van De Walle, C. Grootaert, S. 
Kamiloglu, L. Miclotte, T. Van De Wiele, J. Van Camp, K. 
Dewettinck, T. Desmet, J. Agric. Food Chem. 2017, 65, 6030–6041. 
[12] M. Nakajima, H. Toyoizumi, K. Abe, H. Nakai, H. Taguchi, M. 
Kitaoka, PLoS One 2014, 9, e92353. 
[13] M. Kitaoka, Y. Matsuoka, K. Mori, M. Nishimoto, K. Hayashi, Biosci. 
Biotechnol. Biochem. 2012, 76, 343–348. 
[14] M. Kitaoka, T. Sasaki, H. Taniguchi, J. Biochem. 1992, 112, 40–44. 
[15] Y.-K. Kim, M. Kitaoka, M. Krishnareddy, Y. Mori, K. Hayashi, J. 
Biochem. 2002, 132, 197–203. 
[16] M. Reichenbecher, F. Lottspeich, K. Bronnenmeier, Eur. J. 
Biochem. 1997, 247, 262–267. 
[17] Y. Honda, M. Kitaoka, K. Hayashi, Biochem. J. 2004, 377, 225–232. 
[18] T. Nihira, Y. Saito, M. Nishimoto, M. Kitaoka, K. Igarashi, K. 
Ohtsubo, H. Nakai, FEBS Lett. 2013, 587, 3556–3561. 
[19] K. De Winter, G. Dewitte, M. E. Dirks-Hofmeister, S. De Laet, H. 
Pelantová, V. Křen, T. Desmet, J. Agric. Food Chem. 2015, 63, 
10131–10139. 
[20] K. De Winter, L. Van Renterghem, K. Wuyts, H. Pelantova, V. Kren, 
W. Soetaert, T. Desmet, Adv. Synth. Catal. 2015, 357, 1961–1969. 
[21] K. Hamura, W. Saburi, S. Abe, N. Morimoto, H. Taguchi, H. Mori, H. 
Matsui, Biosci. Biotechnol. Biochem. 2012, 76, 812–818. 
[22] K. Chomvong, V. Kordić, X. Li, S. Bauer, A. E. Gillespie, S.-J. Ha, E. 
10.1002/cbic.201800260
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemBioChem
This article is protected by copyright. All rights reserved.
FULL PAPER    
 
 
 
 
 
Oh, J. M. Galazka, Y.-S. Jin, J. H. D. Cate, Biotechnol. Biofuels 
2014, 7, DOI 10.1186/1754-6834-7-85. 
[23] K. Kino, R. Satake, T. Morimatsu, S. Kuratsu, Y. Shimizu, M. Sato, 
K. Kirimura, Biosci. Biotechnol. Biochem. 2008, 72, 2415–2417. 
[24] J. K. Park, N. O. Keyhani, S. Roseman, J. Biol. Chem. 2000, 275, 
33077–33083. 
[25] H. G. Tran, T. Desmet, K. Saerens, H. Waegeman, S. 
Vandekerckhove, M. D’hooghe, I. Van Bogaert, W. Soetaert, 
Bioresour. Technol. 2012, 115, 84–87. 
[26] H. Nakai, M. A. Hachem, B. O. Petersen, Y. Westphal, K. 
Mannerstedt, M. J. Baumann, A. Dilokpimol, H. a. Schols, J. Ø. 
Duus, B. Svensson, Biochimie 2010, 92, 1818–1826. 
[27] M. Hidaka, M. Kitaoka, K. Hayashi, T. Wakagi, H. Shoun, S. 
Fushinobu, Biochem. J. 2006, 398, 37–43. 
[28] C. M. Bianchetti, N. L. Elsen, B. G. Fox, G. N. Phillips, Acta 
Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2011, 67, 1345–
1349. 
[29] M. Hidaka, Y. Honda, M. Kitaoka, S. Nirasawa, K. Hayashi, T. 
Wakagi, H. Shoun, S. Fushinobu, Structure 2004, 12, 937–947. 
[30] E. C. O’Neill, G. Pergolizzi, C. E. M. Stevenson, D. M. Lawson, S. A. 
Nepogodiev, R. A. Field, Carbohydr. Res. 2017, 451, 118–132. 
[31] M. Nakajima, N. Tanaka, N. Furukawa, T. Nihira, Y. Kodutsumi, Y. 
Takahashi, N. Sugimoto, A. Miyanaga, S. Fushinobu, H. Taguchi, H. 
Nakai., Sci. Rep. 2017, 7, DOI 10.1038/srep42671. 
[32] Y. W. Nam, T. Nihira, T. Arakawa, Y. Saito, M. Kitaoka, H. Nakai, S. 
Fushinobu, J. Biol. Chem. 2015, 290, 18281–18292. 
[33] S. Fushinobu, M. Hidaka, A. M. Hayashi, T. Wakagi, H. Shoun, M. 
Kitaoka, J. Appl. Glycosci. 2011, 58, 91–97. 
[34] M. R. M. De Groeve, M. De Baere, L. Hoflack, T. Desmet, E. J. 
Vandamme, W. Soetaert, Protein Eng. Des. Sel. 2009, 22, 393–399. 
[35] M. R. M. De Groeve, G. H. Tran, A. Van Hoorebeke, J. Stout, T. 
Desmet, S. N. Savvides, W. Soetaert, Anal. Biochem. 2010, 401, 
162–167. 
[36] M. R. M. De Groeve, T. Desmet, W. Soetaert, J. Biotechnol. 2011, 
156, 253–260. 
[37] M. Mayer, B. Meyer, Angew. Chemie - Int. Ed. 1999, 38, 1784–
1788. 
[38] M. Mayer, B. Meyer, J. Am. Chem. Soc. 2001, 123, 6108–6117. 
[39] C. D. Owen, L. E. Tailford, S. Monaco, T. Šuligoj, L. Vaux, R. 
Lallement, Z. Khedri, H. Yu, K. Lecointe, J. Walshaw, S. Tribolo, M. 
Horrex, A. Bell, X. Chen, G. L. Taylor, A. Varki, J. Angulo, N. Juge, 
Nat. Commun. 2017, 8, DOI 10.1038/s41467-017-02109-8. 
[40] J. C. Muñoz-García, M. J. García-Jiménez, P. Carrero, A. Canales, 
J. Jiménez-Barbero, M. Martín-Lomas, A. Imberty, J. L. de Paz, J. 
Angulo, H. Lortat-Jacob, P. M. Nieto, Glycobiology 2014, 24, 1004–
1009. 
[41] Y. Yuan, X. Wen, D. A. R. Sanders, B. M. Pinto, Biochemistry 2005, 
44, 14080–14089. 
[42] Y. Yuan, D. W. Bleile, X. Wen, D. A. R. Sanders, K. Itoh, H. W. Liu, 
B. M. Pinto, J. Am. Chem. Soc. 2008, 130, 3157–3168. 
[43] M. G. Szczepina, R. B. Zheng, G. C. Completo, T. L. Lowary, B. M. 
Pinto, ChemBioChem 2009, 10, 2052–2059. 
[44] J. Angulo, B. Langpap, A. Blume, T. Biet, B. Meyer, N. Rama 
Krishna, H. Peters, M. M. Palcic, T. Peters, J. Am. Chem. Soc. 
2006, 128, 13529–13538. 
[45] S. M. L. Gagnon, M. S. G. Legg, N. Sindhuwinata, J. A. Letts, A. R. 
Johal, B. Schuman, S. N. Borisova, M. M. Palcic, T. Peters, S. V 
Evans, Glycobiology 2017, 27, 966–977. 
[46] E. C. O’Neill, A. M. Rashid, C. E. M. Stevenson, A.-C. Hetru, A. P. 
Gunning, M. Rejzek, S. A. Nepogodiev, S. Bornemann, D. M. 
Lawson, R. A. Field, Chem. Sci. 2014, 5, 341–350. 
[47] S. Kuhaudomlarp, N. J. Patron, B. Henrissat, M. Rejzek, G. 
Saalbach, R. A. Field, J. Biol. Chem. 2018, 293, 2865–2876. 
[48] N. S. Berrow, D. Alderton, S. Sainsbury, J. Nettleship, R. 
Assenberg, N. Rahman, D. I. Stuart, R. J. Owens, Nucleic Acids 
Res. 2007, 35, DOI 10.1093/nar/gkm047. 
[49] F. N. Awad, P. Laborda, M. Wang, A. M. Lu, Q. Li, Z. P. Cai, L. Liu, 
J. Voglmeir, Biochim. Biophys. Acta - Gen. Subj. 2017, 1861, 3231–
3237. 
[50] P.-E. Jansson, J. Lindberg, G. Widmalm, Acta Chem. Scand. 1993, 
47, 711–715. 
[51] R. Stenutz in Bioinformatics for Glycobiology and Glycomics: An 
Introduction, (Eds.: C.-W. von der Lieth, T. Lütteke, M. Frank), 
Wiley-Blackwell, New Jersey, 2009, pp. 311–320. 
[52] P. Colson, R. R. King, Carbohydr. Res. 1976, 47, 1–13. 
[53] M. U. Roslund, E. Säwén, J. Landström, J. Rönnols, K. H. M. 
Jonsson, M. Lundborg, M. V. Svensson, G. Widmalm, Carbohydr. 
Res. 2011, 346, 1311–1319. 
[54] M. U. Roslund, P. Tähtinen, M. Niemitz, R. Sjöholm, Carbohydr. 
Res. 2008, 343, 101–112. 
[55] E. Krissinel, Nucleic Acids Res. 2015, 43, DOI 10.1093/nar/gkv314. 
[56] A. Van Hoorebeke, J. Stout, J. Kyndt, M. De Groeve, I. Dix, T. 
Desmet, W. Soetaert, J. Van Beeumen, S. N. Savvides, Acta 
Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2010, 66, 346–
351. 
[57] Y.-W. Nam, T. Nihira, T. Arakawa, Y. Saito, M. Kitaoka, H. Nakai, S. 
Fushinobu, J. Biol. Chem. 2015, 290, 18281–18292. 
[58] T. Sawano, W. Saburi, K. Hamura, H. Matsui, H. Mori, FEBS J. 
2013, 280, 4463–4473. 
[59] J. Angulo, P. M. Enríquez-Navas, P. M. Nieto, Chem. Eur. J. 2010, 
16, 7803–7812. 
[60] V. Jayalakshmi, N. R. Krishna, J. Magn. Reson. 2002, 155, 106–
118. 
[61] N. R. Krishna, D. G. Agresti, J. D. Glickson, R. Walter, Biophys. J. 
1978, 24, 791–814. 
[62] D. Aerts, T. F. Verhaeghe, B. I. Roman, C. V. Stevens, T. Desmet, 
W. Soetaert, Carbohydr. Res. 2011, 346, 1860–1867. 
[63] T. Nihira, Y. Saito, M. Kitaoka, M. Nishimoto, K. Otsubo, H. Nakai, 
Carbohydr. Res. 2012, 361, 49–54. 
[64] F. N. Awad, P. Laborda, M. Wang, A. M. Lu, Q. Li, Z. P. Cai, L. Liu, 
J. Voglmeir, Biochim. Biophys. Acta - Gen. Subj. 2017, 1861, 3231–
3237. 
[65] W. Kabsch, Acta Crystallogr. Sect. D 2010, 66, 125–132. 
[66] G. Winter, J. Appl. Crystallogr. 2010, 43, 186–190. 
[67] P. R. Evans, G. N. Murshudov, Acta Crystallogr. Sect. D Biol. 
Crystallogr. 2013, 69, 1204–1214. 
[68] P. Skubák, N. S. Pannu, Nat. Commun. 2013, 4, 1–6. 
[69] G. M. Sheldrick, Acta Crystallogr. Sect. A Found. Crystallogr. 2007, 
10.1002/cbic.201800260
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemBioChem
This article is protected by copyright. All rights reserved.
FULL PAPER    
 
 
 
 
 
64, 112–122. 
[70] K. Cowtan, Acta Crystallogr. Sect. D 2006, 62, 1002–1011. 
[71] P. Emsley, K. Cowtan, Acta Crystallogr. Sect. D 2004, 60, 2126–
2132. 
[72] G. N. Murshudov, A. A. Vagin, E. J. Dodson, Acta Crystallogr. Sect. 
D 1997, 53, 240–255. 
[73] J. Painter, E. A. Merritt, J. Appl. Crystallogr. 2006, 39, 109–111. 
[74] I. W. Davis, A. Leaver-Fay, V. B. Chen, J. N. Block, G. J. Kapral, X. 
Wang, L. W. Murray, W. B. Arendall, J. Snoeyink, J. S. Richardson, 
D. C. Richardson, Nucleic Acids Res. 2007, 35, DOI 
10.1093/nar/gkm216. 
[75] S. McNicholas, E. Potterton, K. S. Wilson, M. E. M. Noble, Acta 
Crystallogr. Sect. D Biol. Crystallogr. 2011, 67, 386–394. 
[76] Schrödinger Release 2016-4: Maestro, Schrödinger, LLC, New 
York, NY, 2016. 
[77] M. H. M. Olsson, C. R. Søndergaard, M. Rostkowski, J. H. Jensen, 
J. Chem. Theory Comput. 2011, 7, 525–537. 
[78] E. Harder, W. Damm, J. Maple, C. Wu, M. Reboul, J. Y. Xiang, L. 
Wang, D. Lupyan, M. K. Dahlgren, J. L. Knight, J. W. Kaus, D. S. 
Cerutti, G. Krilow, W. L. Jorgensen, R. Abel, R. A. Friesner, J. 
Chem. Theory Comput. 2016, 12, 281–296. 
[79] B. Han, Y. Liu, S. W. Ginzinger, D. S. Wishart, J. Biomol. NMR 
2011, 50, 43–57. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
10.1002/cbic.201800260
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemBioChem
This article is protected by copyright. All rights reserved.
FULL PAPER    
 
 
 
 
 
Table of Contents  
 
FULL PAPER 
Glycoside phosphorylase (GP) as a 
tool for glycosylation: GPs are 
potential biocatalysts for oligo- and 
polysaccharide synthesis using an 
acceptor and a sugar 1-phosphate 
donor. Herein, we reported the 
synthesis of a disaccharide from 
glucose acceptor and mannose 1- 
phosphate as a non-cognate donor 
using a GP (PsLBP) as a catalyst 
and elucidated the binding of the 
non-cognate donor to the enzyme by 
crystallography and STD NMR.  
 
  
 Sakonwan Kuhaudomlarp, Samuel 
Walpole, Clare E.M. Stevenson, 
Sergey A. Nepogodiev, David M. 
Lawson, Jesus Angulo, Robert A. 
Field* 
Page No. – Page No. 
Unravelling the specificity of 
laminaribiose phosphorylase from 
Paenibacillus sp. YM-1 towards donor 
substrates glucose/mannose 1-
phosphate using X-ray crystallography 
and STD NMR spectroscopy 
 
  
 
 
   
 
 
Glc1P Man1P
50 – 75% 75 – 100%25 – 50%
STD NMR binding epitope of PsLBP
PsLBP structure
10.1002/cbic.201800260
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemBioChem
This article is protected by copyright. All rights reserved.
